Daniel Johnson, MD, is a medical oncologist that specializes in treating patients with melanoma with specific research interests in strategies to overcome immunotherapy resistance and prevent immunotherapy related toxicities. He has multiple peer-reviewed articles and presentations at national meetings pertaining to the management and underlying mechanisms of immune toxicity. Dr. Johnson is a clinical investigator focusing on designing and implementing clinical trials intended to optimize the safety and efficacy of immune checkpoint inhibitors.